| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA936: Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) |
|
Medicine details |
|
| Medicine name | idecabtagene vicleucel (Abecma®) |
| Formulation | intravenous injection |
| Reference number | 3632 |
| Indication | Treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/07/2022 |
| NICE guidance | |